Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Quality indicators (QIs) are measures used to evaluate quality of services but are often underused in pharmacy practice. This study examines trends in 2 established QIs in community pharmacy.
Methods: We conducted a repeated cross-sectional study in Ontario using administrative data collected between 2013 and 2023. We measured 2 QIs designed for pharmacy practice annually: (1) percentage of newly dispensed opioid prescriptions exceeding 50 morphine milligram equivalents (MME), and (2) percentage of eligible patients receiving pharmacist medication reviews within 7 days of hospital discharge. Regional differences were summarized using variance calculations, while temporal trends were analyzed using Mann-Kendall tests.
Results: The opioid indicator demonstrated a consistent decline in the percentage of newly dispensed opioid prescriptions exceeding 50 MME across Ontario, with an absolute reduction of 10.5% from 2013 (25.6%) to 2023 (15.1%). High-dose opioid initiation ranged from 12.8% (Central) to 16.7% (West) in 2023 (range 3.9%, variance 2.3%). Significant time trends were found for all regions, with the largest reductions observed in urban regions. For the medication review indicator, provincial trends declined by 7.6%, from 16.7% in 2013 to 9.1% in 2017, followed by a modest recovery to 12.5% by 2023. Regionally, rates of medication reviews varied, with rural areas maintaining higher uptake rates compared with urban centres. Rates ranged from 7.8% (Toronto) to 16.2% (North) in 2023 (range 8.4%, variance 10.0%). A significant time trend was found only in Eastern Ontario.
Conclusion: Significant declines in high-dose opioid initiation but inconsistent uptake of reviews across regions indicate opportunities for improvement in pharmacy practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373646 | PMC |
| http://dx.doi.org/10.1177/17151635251358873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polydrug abuse: Choice between drugs as a function of concurrent nonindependent ratio sizes.
J Exp Anal Behav
September 2025
Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, USA.
Polydrug abuse is the persistent self-administration of more than one reinforcing drug. The present study provided rhesus monkeys concurrent access to two drugs: 8% alcohol and solutions of either cocaine or methadone. The liquids were available under concurrent nonindependent fixed-ratio (FR) schedules across increasing and then decreasing ratio sizes.
View Article and Find Full Text PDFBackground: People with opioid use disorder (OUD) often exhibit high rates of nonprescribed drug use and low retention on buprenorphine. This study tested the feasibility, acceptability, and preliminary efficacy of an intervention combining peer recovery coaching and CBT4CBT-buprenorphine (CBT4CBT+RC) to reduce nonprescribed drug use and increase buprenorphine retention.
Methods: A randomized trial conducted from December 15, 2020, to November 24, 2021, compared an 8-week CBT4CBT+RC intervention to treatment as usual (TAU).
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes.
JAMA Pediatr
September 2025
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Importance: For the first time in nearly 2 decades, the US infant mortality rate has increased, coinciding with a rise in overdose-related deaths as a leading cause of pregnancy-associated mortality in some states. Prematurity and low birth weight-often linked to opioid use in pregnancy-are major contributors.
Objective: To assess the health and economic impact of perinatal opioid use disorder (OUD) treatment on maternal and postpartum health, infant health in the first year of life, and infant long-term health.
Inadequate Cancer Pain Control after Switching High-Dose Fentanyl to Hydromorphone Injection: A Case Series Highlighting Issues with Conventional Conversion Ratios.
Palliat Med Rep
September 2025
Department of Pharmacy, Yamagata Prefectural Central Hospital, Yamagata, Yamagata, Japan.
Opioid conversion, particularly from high-dose intravenous (IV) fentanyl (>120 mg/day oral morphine-equivalent daily dose per referenced Japanese guidelines) to IV hydromorphone, presents clinical challenges due to inconsistent conversion ratios and lack of robust evidence. Specific approaches used in Japan may require careful evaluation. This report details two advanced cancer patients experiencing inadequate pain control after switching from high-dose IV fentanyl to IV hydromorphone.
View Article and Find Full Text PDFBreastfeeding Continuation at One Month Postpartum Among Women in Treatment for Opioid Use Disorder Who Initiated Breastfeeding: Prevalence and Determinants.
Womens Health Rep (New Rochelle)
August 2025
College of Nursing, Thomas Jefferson University, Phila, Pennsylvania, USA.
Objective: To describe breastfeeding behaviors and determinants in the 1-month postdelivery period among women in treatment for opioid use disorder.
Study Design: Participants completed one questionnaire during pregnancy and one questionnaire at 1 month postpartum. Those who reported on the postpartum questionnaire that they had initiated breastfeeding were included in this analysis ( = 31).